Nabriva Therapeutics

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Poster sessions to highlight pooled results from the pivotal LEAP 1 and LEAP 2 Phase 3 clinical trials Poster sessions to highlight pooled results from the pivotal LEAP 1 and LEAP 2 Phase 3 clinical trials

Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

Nabriva publication of Phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with community-acquired bacterial pneumonia (CABP) Nabriva publication of Phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with community-acquired bacterial pneumonia (CABP)

Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association

DUBLIN, Ireland, Sept.  26, 2019  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that data from its XENLETA™ (lefamulin) and CONTEPO™ (fosfomycin) clinical development programs will be presented at IDWeek 2019, to be held October 2-9 in Washington, D.C.

Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019

Today, we look at Nabriva Therapeutics which has received a tepid reception for the FDA approval of its antibiotic Xenleta on August 19th, 2019.

The Lowdown On Nabriva

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept.  18, 2019  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schroeder will provide a company overview and business update at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 1:50 p.m. ET. The conference is being held at the InterContinental New York Barclay Hotel in New York, NY.   

Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

First IV and oral antibiotic with novel mechanism of action approved by the FDA in nearly two decades, targets the most common CABP pathogens and supports antibiotic stewardship First IV and oral antibiotic with novel mechanism of action approved by the FDA in nearly two decades, targets the most common CABP pathogens and supports antibiotic stewardship

Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.

DUBLIN, Ireland, Sept.  06, 2019  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 338,250 ordinary shares of Nabriva Therapeutics as inducements to 54 newly-hired employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation.

Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept.  06, 2019  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Nabriva has earned a $5 million milestone payment under its licensing agreement with Sinovant Sciences related to the U.S. regulatory approval of XENLETA™ (lefamulin).

Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences

DUBLIN, Ireland, Sept.  05, 2019  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will present data at the ASM/ESCMID Conference September 3-6, 2019 in Boston, MA. This meeting is co-sponsored by the American Society for Microbiology and the European Society for Clinical Microbiology and Infectious Diseases, and addresses drug development to meet the challenge of antimicrobial resistance. 

Nabriva Therapeutics to Present Data at ASM/ESCMID Conference Demonstrating Utility of Xenleta™ (lefamulin) for Patients with Community-Acquired Bacterial Pneumonia (CABP)

CEO of Nabriva Therapeutics Plc (30-Year Financial, Insider Trades) Theodore R Schroeder (insider trades) bought 50,000 shares of NBRV on 08/27/2019 at an average price of $1.79 a share.

Nabriva Therapeutics Plc (NBRV) CEO Theodore R Schroeder Bought $89,500 of Shares

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schroeder will provide a company overview and business update at the 17th Annual Morgan Stanley Global Healthcare Conference on Monday, September 9, 2019 at 9:55 a.m. ET. The conference is being held at the Grand Hyatt hotel in New York, NY.   

Nabriva Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.

Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta

The FDA approved Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV)'s lead antibiotic asset, Xenleta, on Monday for the treatment of community-acquired bacterial infections.

Nabriva Analysts Bullish After FDA OKs Antibiotic; BofA Sees $200M Sales Potential

Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) shares are trading sharply higher, riding on the back of a positive FDA verdict on one of its pipeline assets.

Nabriva Shares Rip Higher Following FDA Nod For Novel Antibiotic

Shares of Nabriva Therapeutics PLC NBRV, -3.07% shot up 27% to pace the premarket gainers in active trading Tuesday, after the biotechnology company said its new drug application (NDA) for the oral and intravenous formulations of Xenleta, a treatment for community-acquired bacteria pneumonia, was approved by the Food and Drug Administration.

Nabriva Therapeutics' stock soars in heavy volume after FDA approves NDA for CABP treatment

Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.

Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4

First New IV and Oral Antibiotic with a Novel Mechanism of Action Approved in Nearly Two Decades Provides Critically Needed Treatment Option for Adult Patients with CABP  

Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacteria Pneumonia (CABP)

Shares of the thinly-traded, micro-cap biotech Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) were  seeing some volatility Friday following an announcement concerning the timeline for its regulatory filing for Contepo.

Nabriva Shares Volatile As Biopharma Updates FDA Filing Timeline

Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Nabriva (NBRV) Stock?

The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.

Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin

Nabriva Therapeutics PLC – ADR shares traded higher last week after the micro-cap biotech said it requested a Type A meeting with the FDA regarding the complete response letter for the new drug application for its investigational compound Contepo to treat complicated urinary tract infections, including acute kidney infections.

FDA Type A Meetings: What You Need To Know

Nabriva Therapeutics, which gained about 8 percent over the previous two sessions in anticipation of a binary event, is giving up those gains and much more after the event materialized as a negative for the company.

Nabriva Shares Tumble After FDA Issues CRL For Antibiotic Candidate

Nabriva Therapeutics PLC shares dropped sharply on Wednesday after the firm received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking marketing approval of Contepo (fosfomycin).

Why the FDA Is Crushing Nabriva’s UTI Treatment

Investors need to pay close attention to Nabriva Therapeutics (NBRV) stock based on the movements in the options market lately.

Do Options Traders Know Something About Nabriva Therapeutics (NBRV) Stock We Don't?

Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

News for Nabriva Therapeutics Stock (NBRV)